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Abstract
Background: The prognostic value of chronic inflammation markers in patients after myocar-
dial infarction (MI) in the era of interventional treatment, statin and aspirin use is still unclear.
Methods: The study was carried out on 107 patients with a first MI who were followed up for
18 months. The end points were cardiac death, reinfarction or unstable angina pectoris. At 10 days
and at 10 weeks we measured C-reactive protein (CRP), fibrinogen, soluble intercellular adhesion
molecule 1 (sICAM-1), erythrocyte sedimentation rate (ESR), white blood cell count (WBC) and
Chlamydia preumoniae antibodies.
Results: During the follow-up period there were 22 events. The patients were divided into two
subgroups: those with recurrent episodes and those without coronary events. Patients with
recurrent episodes had significantly higher values of CRP (7.07 vs. 3.77 mg/l, p = 0.02),
ESR at 1 h (24.3 vs. 13.3 mm; p = 0.01) and sICAM-1 (287.9 vs. 260.9 ng/ml, p = 0.04)
at 10 weeks following infarction. Statistical analysis showed that sICAM-1 > 270 ng/ml,
CRP > 1.83 mg/l and ESR at 1 h > 14 mm measured at 10 weeks were independent risk
factors for recurrent cardiovascular events. In patients with coronary events between the 10th day and
10th week there was no decrease in inflammatory indices (WBC, ESR) and a tendency towards
increasing sICAM-1.
Conclusions: Increased inflammatory markers (CRP, ESR, sICAM-1) at 10 weeks after MI
are independent risk factors for recurrent cardiovascular events. Measuring CRP, ESR and
sICAM-1 at this time point is useful in long-term prognosis after MI. Changes in inflamma-
tory indices (ESR, WBC, sICAM-1) measured at 10 days and 10 weeks following infarction
show a different pattern in patients with and without recurrent cardiovascular events.
(Cardiol J 2007; 14: 50–58)
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Introduction
Numerous clinical and population-based stud-
ies have recently demonstrated that inflammation
plays an essential role in the aetiopathogenesis of
atherosclerosis and in the aetiology of acute coro-
nary syndromes (ACS). Increased levels of C-reac-
tive protein (CRP), interleukin-6 (IL-6), amyloid A
or intercellular adhesion molecule 1 (ICAM-1) ap-
pear to reflect the inflammatory activity within the
atherosclerotic plaque and predict the risk of car-
diovascular events [1–4]. In patients with myocar-
dial infarction the prognostic value of inflammato-
ry markers is obscured by the acute phase reaction
related to myocardial necrosis and in patients un-
dergoing reperfusion by the inflammatory response
after recanalisation of the infarct-related artery.
Furthermore, the time for measuring inflammato-
ry markers to optimise prognosis is not defined.
Recent reports on the atherogenic properties of
CRP have given rise to the question of whether non-
specific, generalised inflammatory stimulation, for
instance that associated with myocardial infarction,
is prognostically unfavourable irrespective of its
origin [5, 6]. The pathological role of CRP could be
significant only in patients with genetically inher-
ited CRP monomerisation or vulnerability of the
immune system, which reacts to mild stimuli with
a higher and prolonged inflammatory response [7].
The purpose of the present study was to evalu-
ate the prognostic value of CRP, soluble intercellular
adhesion molecule 1 (sICAM-1), erythrocyte sedi-
mentation rate (ESR), fibrinogen, and white blood cell
count (WBC) measured after myocardial infarction at
discharge and 10 weeks later when the necrosis-re-
lated inflammatory response is no longer present.
Methods
The study population consisted of 119 patients
admitted with an acute first myocardial infarction
to Cardiac Department No. 1 in Cracow (70 patients)
and the Internal Medicine Ward of the Regional
Hospital in Myslenice (49 patients). Acute myocar-
dial infarction was diagnosed according to the World
Health Organisation (WHO) criteria in force on the
day on which the study began [8]. Patients were re-
cruited into the study on the 10th day after myocar-
dial infarction. Ex-post analysis showed that about
90% of patients had acute coronary events with
ST-segment elevation (STEMI). The exclusion cri-
teria were previous myocardial infarction, cardio-
genic shock, pericarditis and resuscitation. Those
with a history of injury, acute or chronic infection
or inflammation with autoimmune disorders, neo-
plasms, cardiomyopathies, severe valvular heart
disease, atrial fibrillation and liver disease were also
excluded. In most patients the myocardial infarc-
tion was the first manifestation of coronary artery
disease and prior to it they had not received any
medication for coronary artery disease. Patients
were treated with streptokinase or facilliated PCI:
abciximab (Reopro) and half dose tPA (Actilise) or
PCI if the time to admission was under 12 h. Twelve
patients who underwent elective coronary artery by-
pass grafting or percutaneous transluminal coronary
angioplasty at follow-up were excluded from the
final analysis (107 patients). Patients with an end point
such as cardiac death, reinfarction or unstable angi-
na pectoris were withdrawn from the study. Unsta-
ble angina was diagnosed on the basis of recurrence
of resting angina, leading to hospitalisation, and in
the absence of extracardiac causes of ischaemia. In
each case acute ischaemic changes in the ECG were
confirmed.  During the follow-up of 18 months there
were 22 events: 1 cardiac death, 5 re-infarctions and
16 episodes of unstable angina pectoris. On this ba-
sis the patients were divided into those with and
those without complications. Because 7 patients had
episodes before the second measurement (at
10 weeks) the group undergoing analysis and base-
line measurements (at 10 days) consisted of 107 pa-
tients, including 22 with complications (all episodes),
while at 10 weeks the group consisted of 100 patients,
including 15 with complications (late episodes).
Laboratory tests
Biochemical measurements were done at 10 days
and 10 weeks after the infarction. Blood was sampled
from the antecubital vein after 12 h of fasting, centri-
fuged and stored at –70o C until required. CRP was
measured with a high-sensitivity nephelometric as-
say (Dade Behring N High Sensitivity CRP, Germa-
ny). Levels of sICAM-1 were measured using an im-
munoenzymatic assay ELISA (R&D Systems, Inc.
USA). Serum fibrinogen was measured using the
modified Klauss method (Dade Behring Multifibren
U). White blood cells were counted using an automatic
analyser Sysmex K 4500. Sedimentation rate was
measured with the Westergreen method. Chlamydia
pneumoniae antibodies were assessed with Chlamy-
dia pneumoniae IgG ELISA kit and Chlamydia pneu-
moniae IgA ELISA kit (DRG Instruments Gmbh).
Diagnostics of the heart
Morphological and functional indices of the left
ventricle at 10 days and 10 weeks after the infarction
were studied by transthoracic echocardiography
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with a Hewlett-Packard Sonos 2500 and 2.0/2.5 MHz
transducer. Myocardial reperfusion was evaluated
from coronary angiography or reduction in ST-seg-
ment elevations at 90 min by at least 70% in patients
receiving fibrinolysis [9]. Diastolic dysfunction was
diagnosed according to the guidelines of the Euro-
pean Study Group on Diastolic Heart Failure and
according to Oh et al. [10, 11].
Statistical analysis
Because of the skewed distribution a non-par-
ametric Mann Whitney U test was used. Categor-
ical variables were analysed with contingency ta-
bles using the c2 test and the Fisher exact test
where appropriate. Nonparametric Wilcoxon test
was used for paired comparison of changes in in-
flammatory parameters. Pearson’s correlation co-
efficient was used to define the relationships be-
tween the parameters. Univariate analysis and Cox
proportional hazard models were used to define the
effect of independent variables on the occurrence
of episodes.
The presence or absence of a cardiovascular
event was used as a dependent variable in regres-
sion analysis. Variables that in univariate analysis
discriminated between groups with and without
cardiovascular events and that are commonly rec-
ognised as risk factors for the recurrence of cardi-
ovascular events were used as independent varia-
bles in Cox regression models. Variables that
showed a strong cross-correlation were not used in
the models (Table 1). In order to assess relations
between independent variables and the time to car-
diovascular events a Cox regression analysis was
performed. The Cox regression model included
variables chosen by step-wise regression. The fol-
lowing variables were used: age, number of coro-
nary vessels with significant stenoses, anterior
myocardial infarction, reperfusion therapy, ejection
fraction < 45%, diastolic dysfunction, anti-Chlamy-
dia pneumoniae antibodies level IgA > 15.6 EUI and
IgG > 117 EIU, CRP and sICAM-1. Variables that
entered the model (p<0.05) are summarised in
Table 2. The model was adjusted to p < 0.00001.
Quantitative variables were transformed into
categorical ones using the cut-off points under the
receiver operated curve (ROC) and the parameters
were grouped into two categories below and above
the cut-off point. P-values < 0.05 were considered
statistically significant.
Results
The group for analysis included 107 patients:
24 women (22.4%) and 83 men (77.6%) aged
39 – 81 years (mean age 58.3 ± 10). Sixty-two pa-
tients (57.5%) had a history of arterial hypertension,
23 (21.5%) of diabetes mellitus and 74 (69.2%) were
smokers. Excess weight was evident in 51.4%
(n = 55) and obesity in 22.4% (n = 24). Mean total
cholesterol was 5.82 mmol/l, and 46% had LDL cho-
lesterol > 3.5 mmol/l. The most frequent causative
treatment was primary coronary angioplasty (PCI)
53.3% (n = 57) and fibrinolysis 14.9% (n = 16),
whereas reperfusion was not initiated in 31.8%
(n = 34) owing to late hospital admission.
Patients entered the study at 9.8 ± 3.9 days
after pain onset and had a recall visit at 73.7 ± 15.5
days (10.5 weeks). Follow-up lasted 542 days ± 137
(~18 months). Tables 3 and 4 compare demographic
and clinical parameters in the subgroups with and
without events. Early on after the infarction (at 10
days) there were no significant differences in inflam-
matory markers between the groups (Fig. 1–3). At
10 weeks the patients with events had significant-
ly higher readings for the following inflammatory
Table 2. Cox regression analysis.
Variable b Hazard Confidence p
ratio interval
Number of diseased 1.10 0.75 0.50–1.12 0.04
coronary arteries
Diastolic dysfunction 0.98 1.40 1.04–1.89 0.01
after 10 weeks
Anterior wall –2.81 0.08 0.008–0.91 0.01
infarction
sICAM-1 > 270 ng/ml 2.01 4.3 1.17–16.3 0.01
at 10 weeks
ESR >14 mm 0.027 1.01 0.99–1.03 0.02
at 10 weeks
CRP > 1.83 mg/l 2.14 14.39 1.94–106.7 0.04
at 10 weeks
Reperfusion therapy 0.09 0.89 0.53–1.51 0.10
Anty Chlamydia 2.25 10.4 2.43–44.9 0.003
pneumoniae
IgA >15.6 and
IgG >117 EIU
Table 1. Correlations between C-reactive protein
(CRP) and other inflammatory markers (r-Pearson
correlation coefficient).
CRP Fibrinogen ESR WBC
r 0.58 0.40 0.37
p < 0.0001 < 0.05 < 0.05
ESR — erythrocyte sedimentation rate, WBC — white blood cell count
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indices: CRP (mean 7.04 ± 9.2 vs. 3.77 ± 4.9 mg/l,
median: 5.53 vs. 1.78 mg/l, p = 0.02), ESR (mean
24.3 ± 18.6 vs. 13.3 ± 12.4 mm, median: 20 vs.
9 mm, p = 0.01) and sICAM-1 (mean 287.9 ± 57.7
vs. 260.9 ± 52.8 ng/ml, 280.0 vs. 255.2 ng/ml, p = 0.04)
(Fig. 1–3). Fibrinogen showed only a tendency to-
wards higher values (mean 4.23 ± ± 1.28 vs. 3.82 ±
± 1.08, median 4.0 vs. 3.6 g/l, p = 0.15). WBC did
not differ significantly between groups (at 10 days:
mean 7.43 ± ± 2.5 vs. 7.44 ± 1.6, median 6.9 vs. 7.0
thousand/ml, at 10 weeks mean 7.14 ± 1.8 vs. 6.82 ±
± 1.5, median 6.9 vs. 6.5 thousand/ml, p = 0.53). The
patients with complications (n = 22) were more fre-
quently smokers (p = 0.02) and received streptoki-
nase (p = 0.01). This subgroup also had lower HDL
cholesterol level (Table 3). The differences were
not significant at 10 weeks following infarction.
There was no correlation between inflammatory
markers and cholesterol levels or infarct size. ROC
analysis showed that CRP ≥ 1.83 mg/l at 10 weeks was
related to a higher frequency of events. This value
differentiated patients with future events with 56%
sensitivity and 87% specificity. This value was also
used to divide the patients into two subgroups.
These subgroups did not differ significantly in fi-
brinolytic treatment and smoking. ROC analysis for
sICAM-1 and ESR revealed that values: 270 ng/ml
for sICAM-1 and 14 mm for ESR at 1 h differentiat-
ed patients with future events with a specificity of
66% and a sensitivity of 73% for ESR and 63% and
66% respectively for sICAM-1. Kaplan-Meier’s
analysis in groups with CRP below and above
1.83 mg/l or with ESR below 14 mm and above
14 mm showed that the events in patients with high-
er CRP or ESR not were only more frequent but also
occurred earlier (Fig. 4, 5). Cox regression analysis
showed that sICAM-1 > 270 ng/ml, CRP >  1.83 mg/l
and ESR at 1 h > 14 mm measured at 10 weeks
following infarction had an independent influence on
cardiovascular events (Table 2). The type of reper-
fusion therapy affected inflammatory indices at
10 days postinfarction — those who received strep-
tokinase had a higher WBC than the untreated
8.2 vs. 6.9 thousand/ml, p = 0.016) and higher
sICAM-1 than those treated with facilitated PCI (293.7
vs. 234 ng/ml, p = 0.04) (Fig. 6). At 10 weeks postin-
farction inflammatory indices, except ERS which
was highest in the streptokinase subgroup, did not
differ with respect to the type of treatment modal-
ity (Fig. 7). There were no differences in the use of
streptokinase in the subgroups with CRP < and
> 1.83 mg/l (3 and 9 subjects, respectively, p =
= 0.21) and in the subgroups with sICAM-1 < and
> 270 ng/ml (7 and 6 subjects respectively, p = 0.85)
and ESR < and > 14 mm (5 and 8 subjects, respec-
tively, p = 0.08).
The patients with late episodes showed a dif-
ferent dynamic of change in the inflammatory mark-
ers. In this group there was a smaller reduction in
some inflammatory indices between the 10th day and
the 10th week than in the patients with complica-
tions. CRP in patients without episodes decreased
from 16.6 mg/l to 3.76 mg/l compared with 21.33 to
7.04 mg/l in patients with episodes (p for both re-
ductions < 0.001). With respect to sICAM–1 be-
tween the 10th day and 10th week there was an
Table 3. Demographic and clinical characteristics in patients with and without cardiovascular events.
Parameter Events – Events + all p Events + late p
(n = 85)  (n = 22)  (n = 15)
Men 63 (74.1%) 20 (90.9%) 0.16 14 (93.3%) 0.19
Women 22 (25.9%) 2 (9.1%) 0.16 1 (6.7%) 0.19
Age (min/max) 58.4 ± 10 (39/81) 56.4± 9.8 (40/74) 0.46 52.4 ± 8.2 (40/66) 0.03
Body mass index [kg/m2] 27.5 ± 3.9 26.8±3.6 0.41 26.9 0.54
Obesity (BMI ≥ 30 kg/m2) 21 (24.7%) 3 (13.6%) 0.41 3 (20%) 0.94
Abdominal obesity 73 (85.9%) 18 (81.8%) 0.88 13 (87%) 0.74
Arterial hypertension 46 (54.1%) 16 (72.7%) 0.11 11 (73.3%) 0.27
Diabetes mellitus 18 (21.8%) 5 (22.7%) 0.88 3 (20%) 0.91
Family history 43 (49.4%) 10 (45.5%) 0.66 6 (9%) 0.63
Smoking 54 (63.5%) 20 (90.9%) 0.02 14 (93.3%) 0.05
Pack-years 20.1±20 19.9±10.6 0.34 24.3±9.12 0.08
LDL-cholesterol [mmol/l]  3.66±1.1 3.91±1.3 0.62 4.03±1.3 0.50
HDL-cholesterol [mmol/l]  1.26±1.0 1.1±1.1 0.05 1.16±0.3 0.24
Total cholesterol/HDL-cholesterol 4.88±1.7 5.65±1.8 0.06 5.33±1.2 0.14
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Table 4. Clinical characteristics of the subgroups with and without cardiovascular events.
Parameter Events – Events + all p Events + late p
(n = 85) (n = 22)  (n = 15)
Reperfusion therapy:
PCI 40 (47.3%) 6 (27.3%) 0.09 5 (33.3%) 0.48
facilitated PCI 9 (10.5%) 2 (9.1%) 0.85 2 (13.3%) 0.89
PCI + facilitated PCI 49 (57.8%) 8 (36.4%) 0.29 7 (46.6%) 0.66
fibrinolysis 9 (10.5%) 7 (31.8%) 0.01 3 (20%) 0.54
absent 27 (31.7%) 7 (31.8%) 0.80 5 (33.3%) 0.86
Reperfusion 50 (58.8%) 13 (59.1%) 0.83 8 (53.3%) 0.90
Time to reperfusion [h] 6.15 ± 2.9 6.9 ± 2.7 0.42 6.6 ± 2.3 0.57
Number of DCA (> 50% lesions)
(% of patients with coronary
angiography):
1-vessel 31 (58.5%) 3 (27.3%) 0.45 2 (25%) 0.47
2-vessel 20 (37.7%) 3 (27.3%) 0.89 2 (25%) 0.90
3-vessel 2 (3.8%) 5 (45.4%) 0.005 4 (50%) 0.007
Medication: abciximab 20 (23.5%) 4 (18.2%) 0.80 3 (20%) 0.97
Medication on discharge:
ASA 83 (97.6%) 22 (100%) 0.87 15 (100%) 0.69
statin 74 (87%) 16 (72.7%) 0.19 10 (66.7%) 0.10
b-blocker 83 (97.6%) 21 (95.5%) 0.86 15 (100%) 0.69
ACEI 59 (69.4%) 19 (86.4%) 0.18 12 (80%) 0.59
ticlopidyne 4 weeks 24 (28.2%) 3 (13.6%) 0.25 2 (13.3%) 0.37
cropidogrel 4 weeks 10 (11.7%) 1 (4.5%) 0.54 1 (6.6%) 0.89
Medication at 10 weeks:
ASA 83 (97.6%) 15 (100%) 0.68
statin 75 (88.2%) 14 (93.3%) 0.89
b-blocker 83 (97.6%) 15 (100%) 0.68
ACEI 53 (62.4%) 12 (75%) 0.59
Infarct site:
inferior 34 (40%) 11 (50%) 0.39 8 (53.3%) 0.33
anterior 23 (27.1%) 2 (9.1%) 0.15 0 0.01
lateral 11 (12.9%) 4 (18.2%) 0.77 4 (26.7%) 0.32
anterolateral 10 (11.8%) 3 (13.6%) 0.89 2 (13.3%) 0.79
posterior 7 (8.2%) 2 (9.1%) 0.88 1 (6.7%) 0.75
LVEF 10 days  51.9±7.0% 52.8±8.9 0.70 52.7±9.4 0.89
LVEF 10 weeks 53.7±6.6% 50.6±8.7 0.19
LVEDV [ml] 10 days 130.5±35.8 140.9±38.8 0.24 143±42 0.27
LVESV [ml] 10 days 64±20.4 74±25.4 0.19 71±24 0.19
LVEDV [ml] 10 weeks 126.5±32.8 146±38 0.08
LVESV [ml] 10 weeks 60.1±20.4 78.2±26.5 0.01
WMSI 10 days 1.43±0.22 1.39±0.25 0.33 1.44±0.22 0.73
WMSI 10 weeks 1.35±0.21 1.38±0.28 0.90
Infarct size:
AUC CK 79392±65571 81130±56615 0.78 89253±60969 0.49
infarct size 1–3 44 (51.8%) 11 (50%) 0.92 9 (60%) 0.75
number of ECG leads 4–6 31 (36.4%) 7 (31.8%) 0.87 5 (33.3%) 0.81
with ST elevations > 6 10 (11.8%) 4 (18.2%) 0.65 1 (6.7%) 0.89
PCI — percutaneous coronary intervention, DCA — diseased coronary arteries, ASA — acetylsalicylic acid, ACEI — angiotensin converting enzyme
inhibitor, LVEF — left ventricular ejection fraction, LVEDV — left ventricular end-diastolic volume, LVESV — left ventricular end-systolic volume,
WMSI — wall motion score index, AUC — area under curve, CK — creatine kinase
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increasing tendency (medians: 282.1 and 287.9 ng/ml)
in patients with episodes as compared with a de-
creasing tendency (p = 0.18) in patients without
episodes (medians: 265.5 and 260.9 ng/ml). WBC
in patients with episodes remained unchanged be-
tween the 10th day and the 10th week (from 7.49 ± 3.0
to 7.15 ± 1.8 thousand/ml, p = 0.42), whereas in
patients without complications it decreased (from
7.44 ± 1.67 to 6.82 ± 1.58 thousand/ml, p = 0.004).
Similar results were obtained for ESR: in patients
with episodes ESR did not decrease (from 38.9
to 24.3 mm, p = 0.06), whereas in patients without
complications a reduction was evident (from
32.1 to 13.3 mm, p < 0.0001).
CR
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10 days 10 weeks
0
5
10
15
16.6 ± 8.8
3.7 ± 4.9
19.7 ± 10.5
NS
p = 0.02
7.0 ± 9.2
20
Events – Events +
Figure 1. C-reactive protein (CRP) in patients with and
without complications at 10 days and 10 weeks follo-
wing infarction.
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Figure 2. Soluble intercellular adhesion molecule 1
(sICAM-1) in patients with and without complications at
10 days and 10 weeks following infarction.
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Figure 3. Erythrocyte sedimentation rate (ESR) at 1 h in
patients with and without complications at 10 days and
10 weeks following infarction.
Figure 4. Kaplan-Meier curve for events in groups with
C-reactive protein < 1.83 mg/l and ≥ 1.83 mg/l; long-
-rang test p = 0.006
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Discussion
Evidence shows that inflammation is not lim-
ited only to a single plaque but involves the whole
vascular system [12, 13]. Apart from the infarct size,
the inflammatory response after acute coronary
episodes may be modified by therapy (thromboly-
sis, statins and aspirin), which may blunt the rela-
tionship between the level of inflammatory mark-
ers and cardiovascular risk. Although according to
the guidelines of the American Heart Association [14]
the measuring of inflammatory markers is not rec-
ommended in secondary prevention, their prognos-
tic value in patients after myocardial infarction has
been demonstrated [15–17]. In the present study
there was a significant difference in CRP levels at
10 weeks after myocardial infarction between patients
with secondary cardiovascular events (7.04 mg/l) and
patients without such complications (3.77 mg/l) at
long-term follow-up. Multifactorial analysis also re-
vealed that higher ESR, CRP, sICAM-1 at 10 weeks
after myocardial infarction were independent risk
factors for cardiovascular events.
Slightly different results were obtained in the
THROMBO trial [16], in which measurements were
made at 8 weeks following infarction. Of 957 pa-
tients CRP was significantly higher in patients with
events, constituting 7%. Univariate analysis showed
a higher risk in patients with CRP in the highest
quartile, but multifactorial analysis revealed that
inflammatory markers such as CRP and serum
amyloid A (SAA) were not independent risk factors
for cardiovascular events. It is noteworthy that 20%
of patients had a history of previous myocardial in-
farction and cannot be compared directly with the
present homogenous group, and that the group of
patients with complications during a follow-up of
2 years constituted only 7% of the whole popula-
tion, decreasing the statistical power.
In the Japanese OACIS study [17] in a popu-
lation of 1307 patients at 25 days following infarc-
tion the investigators found that CRP levels did not
correlate with the infarct size and that CRP was
an independent prognosticator of death after my-
ocardial infarction at long-term follow-up. The
present findings are compatible with the results
of the CARE study [18]. In this study CRP was
measured between 3 and 21 months following inf-
arction in a population of 4159 patients. A subgroup
Figure 5. Kaplan-Meier curve for events in groups at
10 weeks with erythrocyte sedimentation rate (ESR) at
1 h < 14 mm and ≥ 14 mm (log rang test p = 0.009).
Figure 7. Levels of erythrocyte sedimentation rate (ESR)
(2 h) at 10 weeks  in group with different kind of reper-
fusion treatment.
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Figure 6. Levels of soluble intercellular adhesion mole-
cule 1 (sICAM-1) at 10 days in group with different kind
of reperfusion treatment.
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of 391 patients with re-infarction or cardiac death
was compared with 391 matched controls without
cardiovascular events. The patients were ran-
domised to receive pravastatin or placebo. CRP
levels were higher in patients with cardiovascular
events than in the controls, 5.6 vs. 4.8 mg/l
(p = 0.03), and multifactorial analysis revealed that
CRP was an independent risk factor for cardio-
vascular events.
The present study shows that the 10th week
following infarction is a good time point to meas-
ure inflammatory indices. We should also bear in
mind that over three quarters of the patients re-
ceived statins (simvastatin in 90% of cases), which
can reduce CRP levels within several weeks [19].
In spite of this, both subgroups showed higher
chronic CRP levels. This is in line with previous
findings that patients with ischaemic heart disease
had CRP levels twice as high as healthy controls
[18, 20]. Jenkins et al. [21] also suggest that beta
blockers may decrease CRP levels. These drugs
could blunt the effect of CRP on the study end points
and consequently blunt the relationships in multi-
factorial analysis. The present finding could also
have been modified by postinfarction changes in life-
style, such as cessation of smoking and increased
physical activity, which reduce CRP and fibrinogen
levels but not ICAM-1. In the present study the fact
that patients with cardiovascular events identified
10 days following infarction more frequently re-
ceived fibrinolysis could be the confounding factor
in the assessment of chronic inflammation. Strep-
tokinase resulted in higher levels of sICAM-1 at
10 days and ESR at 10 weeks, although without ef-
fects on CRP at 10 weeks. In patients with cardio-
vascular events identified at 10 weeks following in-
farction and in patients with CRP > 1.83 mg/l there
were no differences in the use of streptokinase,
a situation similar to that of patients with
sICAM-1 > 270 ng/ml. These data indicate that in
the present study the type of reperfusion did not
affect the levels of inflammatory markers in the two
subgroups. A comparison of factors that could in-
fluence end points in the subgroups showed that
cardiovascular complications were more frequent
in patients with multivessel disease; infarct size and
infarct location did not influence the occurrence of
cardiovascular events. The difference in frequency
of anterior myocardial infarction was caused by ear-
ly events (before the 10th week after myocardial in-
farction) in two patients with anterior myocardial
infarction. The group was therefore homogenous,
and the difference in coronary events was caused
by plaque instability (unstable angina and acute
myocardial infarction were responsible for 95% of
all end points) and not by electrical instability, which
is influenced by the infarct area, ejection fraction
and left ventricular end-diastolic volume. Plaque in-
stability is also responsible for the absence of a
strong correlation between these prognostic factors
and the recurrence of cardiovascular events in the
study subgroup. Another factor may be the dura-
tion of follow-up (which was too short for the de-
velopment of congestive heart failure) and the small
numbers of patients in the subgroups, a limitation of
our study. Because our study was directed at assess-
ing the clinical prognostic utility of inflammatory
markers, our group, with different types of reper-
fusion therapy and with patients that did not receive
reperfusion therapy at all, corresponded to a real-life
population of myocardial infarction patients, but this
of course is another limitation of the study in case of
small patient number in the subgroups.
The pattern of changes in inflammatory mark-
ers was significantly different between the groups
during follow-up. In patients without cardiovascu-
lar events between the 10th day and the 10th week
following infarction white blood cell count was
markedly lower but this was not the case in patients
with cardiovascular events. Similarly, ESR did not
decrease in patients with cardiovascular events and
only a tendency for sICAM-1 was observed. These
data suggest that patients with secondary cardio-
vascular events constitute a group of subjects with
prolonged inflammatory reaction related to the
presence of unstable atherosclerotic plaques or that
inflammatory activation and enhanced expression
of adhesive molecules on the endothelium result
from hyperactivity of the immune system in re-
sponse to mild stimuli.
Conclusions
1. Increased inflammatory indices (CRP, ESR,
sICAM-1) at 10 weeks after infarction are in-
dependent predictors of secondary cardiovas-
cular events. Measurements of CRP, ESR or
sICAM-1 are useful in long-term prognosis af-
ter myocardial infarction.
2. Inflammatory indices (ESR, WBC) measured at
10 days and 10 weeks following infarction show
a different pattern of changes in patients with
and without cardiovascular events
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